Form 4 for DNLI Denali Therapeutics Inc.

Accepted 2024-08-22 00:00:00 ET · period of report 2024-08-20 · accession 0001714899-24-000194 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
M	2024-08-22	2024-08-20+	DNLI	Ho Carole	Chief Medical Off	S - Sale	$24.49	-22.5K	118.8K	-16%	-$549.9K

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2024-08-20	S	D	2,453	$23.79	138,815	D	—	—	(F2) The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $23.62 to $23.79 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. (F3) Includes 118,810 Unvested RSUs.
2	Common	Common Stock	2024-08-21	S	D	14,098	$24.41	124,717	D	—	—	(F5) The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $23.84 to $24.83 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. (F3) Includes 118,810 Unvested RSUs.
3	Common	Common Stock	2024-08-21	S	D	5,907	$24.96	118,810	D	—	—	(F6) The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $24.84 to $25.21 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. (F3) Includes 118,810 Unvested RSUs.